Jonathan L. Kaufman, MD
Associate Professor and Associate Vice-Chair for Quality and Safety,
Department of Hematology and Medical Oncology
Emory University School of Medicine
Atlanta, GA

Jonathan L. Kaufman, MD, has disclosed having financial arrangements
or affiliations with the following commercial interest(s) whose products
or services may be mentioned in this activity.
Research Grant: Merck, Novartis, Onyx
Consultant: Incyte, Pharmacyclics, Celgene

Course Director

Agne Paner, MD
Assistant Professor Medicine, Division of Hematology/Oncology Director, Coleman Foundation Comprehensive Multiple Myeloma Clinic

Agne Paner, MD has disclosed having financial arrangements or affiliations with the following commercial interest(s) whose products or services may be mentioned in this activity.
Member Speakers’ Bureau: Celgene, Onyx/Amgen
Consultant: Takeda

Accredited By

Rush University Medical Center

Co-provided By

This activity is co-provided by Rush University and PleXus Communications.

Activity Details

Credit Type: AMA, ANCC
Credit Amount: 1.0
Expiration Date: July 11, 2017
Estimated Time to Complete Activity: 60 minutes
Registration Required: No
Fee for Activity: There is no fee for participating in this activity.

Activity Description

This activity will provide the most up-to-date information on current therapeutic approaches and promising advances in treating patients with multiple myeloma.

Learning Objectives

After completing this program, participants should be able to:

  1. Describe current treatment strategies and supporting rationales for the individualized management of transplant-eligible, as well as elderly multiple myeloma patients throughout the lifecycle of the disease
  2. Assess the shifting treatment paradigms of multiple myeloma including emerging regimens used in smoldering myeloma, primary therapy, consolidation therapy, maintenance therapy, and relapsed/ refractory disease
  3. Evaluate finalized and ongoing clinical trial data utilizing standard of care and/or investigational therapies that have the potential to enhance clinical outcomes in newly diagnosed, relapsed/refractory, and non-transplant eligible patients
  4. Summarize emerging new classes of therapeutics and potential combinations, primarily in the relapsed/ refractory setting

Target Audience

Healthcare providers who are involved with the treatment of patients with multiple myeloma.

Requirements for Successful Completion

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Conflict of Interest Policy / Disclosure Statement

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Accreditation Statement

Rush University Medical Center is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide education for the healthcare team.

Rush University designates this online activity for one (1.0) Continuing Education credits

Instructions for Receiving Credit

Participants must complete and submit the online CE evaluation form at the conclusion of the activity and achieve a passing score of 75% or better. Certificates will be generated upon completion and submission of the evaluation form.

Statement of Commercial Support

This activity is supported by independent educational grants from AbbVie, Celgene Corporation, Pharmacyclics, Inc. and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., Millennium: The Takeda Oncology Company and Spectrum Pharmaceuticals Inc.

Disclaimer Statement / Disclosure of Unlabeled Use

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Rush University, PleXus Communications, and/or the commercial supporters. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Rush University, PleXus Communications and/or the commercial supporters. Rush University’s ANCC accreditation status does not imply endorsement by Rush or ANCC of any commercial products displayed in conjunction with this activity. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Contact Information for Questions about the Activity

Hardware / Software Requirements

Our educational activities are available on Mac, PC, and Multi-Touch devices. For the best online experience, we recommend using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox or Safari.

Depending on your browser of choice, additional software, such as Adobe Reader®, may be required.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.